Ramucirumab: hitting another target in gastric cancer

References

• Globocan 2008 Cancer Fact Sheet: stomach cancer incidence and mortality worldwide in 2008 [webpage on the Internet]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp. Accessed October 28, 2014.
   Google Scholar
• Survival rates for stomach cancer, by stage. Atlanta, GA: American Cancer Society; 2014 [updated May 27, 2014]. Available from: http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-survival-rates. Accessed September 12, 2014.
   Google Scholar
• Thompson GB, Van Heerden JA, Starr MG. Adenocarcinoma of the stomach: are we making progress? Lancet. 1993;342(8873):713–718.
   Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Bornschein J, Rokkas T, Selgrad M, Malfertheiner P. Gastric cancer: clinical aspects, epidemiology, and molecular background. 2011; 16(Suppl 1):45–52.
   Google Scholar
• Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.
   Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim HJ, Kim SY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24(11):2850–2854.
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–1529.
   PubMed Web of Science ®Google Scholar
• Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer: a systematic analysis of data from the literature. J Cancer. 2012;3:137–144.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a Phase III, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes: a systematic review. Int J Cancer. 2012;130(12):2845–2856.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
   PubMed Web of Science ®Google Scholar
• Zhao ZQ, Yang S, Lu HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 2012;5(2):415–419.
   PubMed Web of Science ®Google Scholar
• Cabuk D, Basaran G, Celikel C, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1α and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology. 2007;72(1–2):111–117.
   Web of Science ®Google Scholar
• Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24(2):228–240.
   PubMed Web of Science ®Google Scholar
• Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201–5206.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase III study. J Clin Oncol. 2011;29(30):3968–3976.
   PubMed Web of Science ®Google Scholar
• Shah M, Van Cutsem E, Kang YK, et al. Survival analysis according to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer [abstract]. J Clin Oncol. 2012;30(Suppl 4):abstract 5.
   Web of Science ®Google Scholar
• Shen L, Li J, Xu J, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, Phase III study (AVATAR study). Gastric Cancer. February 21, 2014.
   Google Scholar
• Fong GH, Rossant J, Gertsentein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regualting the assembly of vascular endothelium. Nature. 1995;376(6535):66–70.
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780–787.
   PubMed Web of Science ®Google Scholar
• Fuchs C, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD):an international, randomised, multicentre, placebo-controlled, Phase III trial. Lancet. 2014;383(9911):31–39.
   PubMed Web of Science ®Google Scholar
• Ford H, Marshall A, Wadsley J, et al. Cougar-02: a randomized Phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma [abstract]. J Clin Oncol. 2013;31(Suppl 4):abstract LBA4.
   Google Scholar
• Wilke H, Van Cutsem E, Oh SG, et al. RAINBOW: a global, Phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE) [abstract]. J Clin Oncol. 2014;32(Suppl 3):abstract LBA7.
   Web of Science ®Google Scholar
• Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized Phase III trial. J Clin Oncol. 2012;30(17):2119–2127.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network; Analysis Working Group: Dana-Farber Cancer Institue; Institute for Systems Biology, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. Epub July 23, 2014.
   Google Scholar